The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295.
 
Nabil Adra
Research Funding - Genentech (Inst); Merck (Inst)
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); SOTIO (Inst); US Oncology (Inst)
Other Relationship - ABIM Subspecialty Board
 
Hristos Z. Kaimakliotis
No Relationships to Disclose
 
Shuchi Gulati
Consulting or Advisory Role - Puma Biotechnology
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Conquer Cancer Foundation
 
Neda Hashemi
No Relationships to Disclose
 
Roberto Pili
Consulting or Advisory Role - Exelixis; Ipsen; Prometheus
Research Funding - Active Biotech; ARIAD; Millennium; Peregrine Pharmaceuticals; Pfizer; Syndax